Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...
Unlock the key principles that separate clear, compelling speakers from the rest. These straightforward methods will help you ...
Utilizing its innovative ADC payload platform, Akari is advancing a new class of immuno-oncology ADCs built on the platform ...
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine ...